Acute Respiratory Distress Syndrome after Topotecan Therapy in a Patient with Small Cell Lung Cancer / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
; : 142-146, 2008.
Article
em Ko
| WPRIM
| ID: wpr-182743
Biblioteca responsável:
WPRO
ABSTRACT
Small cell lung cancer is characterized by an aggressive clinical course and a high tendency for early dissemination in spite of a good chemotherapy response. Topotecan is a topoisomerase I inhibitor, and it is used as second-line treatment for small cell lung cancer. The reported dose-limiting adverse reactions to topotecan are mainly hematologic. Yet pulmonary toxicity associated with topotecan is known to be rare. We report here on a case that showed the development of acute respiratory distress syndrome during the 3rd cycle of topotecan chemotherapy in a patient with small cell lung cancer. He developed dyspnea and respiratory failure, and the chest CT scan revealed diffuse ground-glass opacity that was probably due to chemotherapy-related pulmonary toxicity. He finally died of acute respiratory distress syndrome.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Síndrome do Desconforto Respiratório
/
Insuficiência Respiratória
/
Tórax
/
Carcinoma de Células Pequenas
/
DNA Topoisomerases Tipo I
/
Topotecan
/
Dispneia
/
Carcinoma de Pequenas Células do Pulmão
Limite:
Humans
Idioma:
Ko
Revista:
Tuberculosis and Respiratory Diseases
Ano de publicação:
2008
Tipo de documento:
Article